Clinical trial
Chart Review: Unresectable/Metastatic Cholangiocarcinoma Treated With…
NCT00320918 · University of New Mexico, Other · Terminated
Key facts
| NCT number | NCT00320918 |
|---|---|
| Title | Chart Review: Unresectable/Metastatic Cholangiocarcinoma Treated With Irinotecan, Capecitabine and Celecoxib |
| Official title | Chart Review on Patients With Unresectable/Metastatic Cholangiocarcinoma Treated in the UNM Cancer Center With a Combination of Irinotecan, Capecitabine and Celecoxib |
| Lead sponsor | University of New Mexico, Other |
| Status | Terminated |
| Study type | Observational |
| Conditions | Cholangiocarcinoma |
| Enrollment | 10 |
| Start date | Nov 1, 2005 |
| Primary completion | Aug 1, 2006 |
| Completion | Oct 1, 2006 |
| First posted | May 3, 2006 |
| Last update posted | Jan 12, 2024 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: